Clinical Trial

METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

Name: METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer — clinical trial record (NCT06884345)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

To further evaluate and observe the efficacy and safety of solantinib combined with METR-NK neoadjuvant therapy for advanced epithelial ovarian cancer in patients with advanced epithelial ovarian cancer by using solantinib combined with METR-NK neoadjuvant therapy

Trial Details

NCT Number	NCT06884345
Lead Sponsor	Anhui Provincial Cancer Hospital
Conditions	Ovarian Cancer
Enrollment	28 participants
Start Date	2025-03-13
Primary Completion	2026-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-03-19